Method for multiple sclerosis treatment and prophylaxis by therapy leptospira infecion

A technology for multiple sclerosis and leptospirosis, applied in allergic diseases, antibody medical ingredients, pharmaceutical formulations, etc., can solve the problem of no pathogen, no disease-specific treatment or diagnosis, etc.

Inactive Publication Date: 2007-08-01
UNIVERSITY OF COPENHAGEN
View PDF13 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0124] In conclusion, even though advances have been made in the treatment and diagnosis of MS, there is as yet no art-recognized causative agent, and thus no specific treatment or diagnosis of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for multiple sclerosis treatment and prophylaxis by therapy leptospira infecion
  • Method for multiple sclerosis treatment and prophylaxis by therapy leptospira infecion
  • Method for multiple sclerosis treatment and prophylaxis by therapy leptospira infecion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0189] How to prevent and treat MS

[0190] A direct consequence of understanding the causative factors of MS is the possibility of designing disease-specific preventive and therapeutic approaches. Because of the evidence presented here for the pathogenic role of L. interrogans or similar Leptospira species / strains, various immunoprophylactic and therapeutic measures are possible, as are antibacterial drug regimens. Interestingly, active immunotherapy and active immunoprophylaxis use the same means and measures, differing only in the timing of treatment relative to disease onset.

[0191] The genome of L. interrogans has been sequenced, thus making it possible to identify a number of protein antigens that can be used as immunogenic agents for prophylaxis or for active specific immunotherapy.

[0192] A list of preferred specific immunogens includes:

[0193] a) A preparation of a live Leptospira species, which is non-pathogenic in humans, which preferentially immunological...

Embodiment 1

[0310] Endemic stability studies in search of diseases with unknown etiology

[0311] Emerging and re-emerging diseases such as MS are receiving increasing attention in the scientific community. The concern is based on the idea that disease emerges as a result of novel interactions between humans and reservoirs of disease agents. While this is true in many cases, the present invention is based on the idea that what appears to be a disease occurrence may in fact be a zoonosis reflecting endemic stability. Disease thus arises from lack of contact with nature rather than increased contact.

[0312] Therefore, studies explaining this finding were based on studies of endemic stability, where the disease in humans with an assumed unknown etiology (MS in this case) was in fact mirrored in the reservoir host (Rattus norvegicus in this case). Endemic stability of zoonotic diseases. The present invention is believed to be the first to use endemic stability studies to identify patholo...

Embodiment 2

[0354] Search for zoonotic diseases that may cause MS

[0355] Due to the unclear epidemiology of multiple sclerosis (MS), this disease was chosen for preliminary trials in the search for zoonotic diseases reflecting endemic stability. Reports of gradients in eg Australia (Hammond et al. 2000) increase the likelihood that analyzes may yield evidence that may further understand the disease. This can also be extended to a world scale, where the pattern shows promise for a particular factor with this unique distribution (Fig. 2a). On the surface, Eurasians appear to be at greater risk than other ethnic groups. Therefore, all animals associated with wild and domesticated cultures in Europe are intriguing when attempting to link the course of the disease to possible reservoir hosts.

[0356] The reservoir hosts that are the most likely candidates are provided here based on spatial correlation, without referring to all possible reservoir hosts investigated in this approach. There...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides novel therapies and novel prophylactic methods for multiple sclerosis. Also provided are novel diagnostic methods. The invention resides in the finding that multiple sclerosis most likely is caused by chronic infection with a microorganism that cross-reacts immunologically with the spirochete Leptospira interrogans, which normally infects the brown rat.

Description

field of invention [0001] The present invention relates to the fields of treatment, prevention, diagnosis and monitoring of multiple sclerosis (MS). In particular, the present invention proposes to treat and prevent MS by targeting pathogenic factors associated with Rattus norvegicus. In this context, the present invention provides a human therapy by targeting the spirochetes Leptospira, in particular L. interrogans, which endemicly infect rats. Background of the invention [0002] Current knowledge about multiple sclerosis [0003] The following background notes on MS are largely taken directly from the Multiple Sclerosis International Federation homepage www.msif.org .. When including other sources of information, provide references. [0004] Multiple sclerosis is a particularly difficult disease to study for a number of reasons: [0005] • The etiology is unknown, although it is generally believed to be a combination of genetic, immune, and environmental factors. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/02A61K39/00
CPCA61K39/0008A61K2039/53A61K39/0225A61K2039/58A61P25/00A61P37/00Y02A50/30A61K39/02
Inventor P·M·詹森
Owner UNIVERSITY OF COPENHAGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap